Skip to Content
A home for paediatricians. A voice for children and youth.

Position statement

CPS

Selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors in pregnancy: Infant and childhood outcomes

Posted: Jul 29, 2021

The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.

Principal author(s)

Leonora Hendson, Vibhuti Shah, Sandra Trkulja; Canadian Paediatric Society, Fetus and Newborn Committee

Paediatr Child Health 2021 26(5): 321 (Abstract).

Abstract

This position statement provides guidance for the monitoring, care, and follow-up of newborns exposed to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) in utero. Depression and anxiety are common during pregnancy and postpartum. While there are risks to taking medications during pregnancy, untreated or incompletely managed depression and anxiety also carry risks for the newborn. Poor neonatal adaptation syndrome (PNAS) occurs in one-third of newborns exposed to SSRIs or SNRIs in utero, and is generally mild and self-limiting. The low levels of SSRIs and SNRIs excreted in breast milk are compatible with breastfeeding. Persistent pulmonary hypertension of the newborn and congenital heart defects are rare associations of exposure to SSRIs or SNRIs in utero. There are inconsistencies in the literature regarding neurodevelopmental outcomes, specifically autism spectrum disorder and attention-deficit hyperactivity disorder. The inconsistencies likely relate to other factors (i.e., genetics, maternal depression, lifestyle, comorbidities), rather than exposure to SSRIs or SNRIs in utero. Health care providers and parents should be reassured that PNAS is generally treatable with non-pharmacological measures, and that the risk of serious adverse effects from exposure to SSRIs or SNRIs in utero is low.

Keywords: Poor neonatal adaptation syndrome; Pregnancy; Selective serotonin reuptake inhibitors; Serotonin-norepinephrine reuptake inhibitors

In Canada, the annual and lifetime prevalence of major depressive disorder (MDD) in the general population is 4.7% and 11.3%, respectively [1]. Women have a greater annual prevalence of MDD compared with men (4.9% versus 2.8%) [1]. Perinatal depression, occurring during pregnancy and in the first year postpartum, is one of the most common morbidities of pregnancy and the postnatal period, with an estimated prevalence of 7.5% during pregnancy and 6.5% in the first 3 months postpartum [2][3]. When minor depressive disorders are considered, these rates increase to 18.4% and 19.2% respectively [2][3]. Similarly, the overall prevalence of a clinical diagnosis of any anxiety disorder is 15.2%, and 4.1% for a generalized anxiety disorder [4]. The prevalence for self-reported anxiety symptoms is 18.2%, increasing to 24.6% in the third trimester [4]. Postnatally, the prevalence of anxiety symptoms overall is 15% [4]. If untreated, maternal depression and anxiety can affect the pregnancy (e.g., via poorer nutrition and medical care, increased smoking, or substance misuse), the newborn (e.g., being small for gestational age, born preterm, greater rates of neonatal intensive care unit (NICU) admission, lower rates of breastfeeding [5]-[8]), infant development (e.g., lower quality mother-infant interactions, and later, higher rates of emotional, behavioural, and academic problems [9][10]), maternal mental health (e.g., MDD relapse [11]), and family functioning [2][10][12].

Although non-pharmacological treatments are considered first line [2][12], pharmacological therapy may be required. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the most commonly prescribed antidepressants in pregnancy [13]. In the United States and Europe, 6% and 3.8% of women take an SSRI or SNRI respectively during pregnancy, with lesser prevalence before pregnancy or in the first trimester compared with later in pregnancy [13]-[15]. It is important to balance the risks and benefits of SSRI and SNRI use in pregnancy and postpartum versus the risks of inadequately treating maternal depression or anxiety on the health of the mother, her pregnancy, family life, and child health. Discussions about a person’s intent to become pregnant and the safety of treatments during pregnancy should be part of assessing, managing, and counselling women of childbearing age with experience of depression or anxiety [2][12][16][17]. Together with individualized assessment and discussion of options with a clinician, families can access helpful online resources at mothertobaby.org and medicinesinpregnancy.org.

This statement updates a previous CPS document on the risks of exposure to SSRIs or SNRIs in pregnancy on infant outcomes [18] with additional information on risks for neurodevelopmental outcomes. The following questions have helped to focus recommendations:

  1. Are SSRI and SNRIs safe to use in pregnancy regarding risk for congenital malformations, pregnancy outcomes (preterm birth and low birth weight (LBW)), poor neonatal adaption syndrome (PNAS), persistent pulmonary hypertension of the newborn (PPHN), autism spectrum disorder (ASD), and attention-deficit hyperactivity disorder (ADHD)?
  2. What monitoring is required in the neonatal period for infants exposed to SSRI or SNRIs in utero?
  3. Should mothers using an SSRI or SNRI breastfeed?

Literature search strategy

Search strategies were conducted in October 2018, using MEDLINE, EMBASE, CINAHL, and Cochrane Database of Systematic Reviews to capture the literature published since the previous statement review [18]. The following search terms were used: selective serotonin reuptake inhibitors or SSRI, OR serotonin-norepinephrine reuptake inhibitors or SNRI, AND pregnancy or expectant mothers, OR postnatal period or postpartum, OR pregnancy complications. Bibliographies were also reviewed for pertinent references. An important limitation of the literature is that the use of SSRI and SNRIs during pregnancy is a marker for a population of women with different risk factors from the general population of pregnant women [9][19]. Most studies are thus confounded by indication and an inability to fully control for underlying maternal depression, severity of depression, or risk factors associated with maternal depression. Available human data from population-based epidemiological studies or systematic reviews are presented when available. Text and tables cite these studies first, followed by systematic reviews by year of publication, with the most recent studies first.

Are SSRIs and SNRIs safe to use in pregnancy?

Congenital malformations

Information on the possible teratogenic effects of individual SSRIs or SNRIs has been controversial, whether based on studies of population or meta-analysis (Table 1).

Using multicentre, population-based, case-control data from the United States, sertraline was the most commonly used SSRI, and no association of sertraline with any specific congenital malformation in infants has been found [20]. Paroxetine has been associated with anencephaly, atrial septal defects (ASDs), right ventricular outflow tract obstruction (RVOTO) defects, gastroschisis, and omphalocele [20]. Fluoxetine has been associated with RVOTO defects and craniosynostosis [20]. Similarly, using a population-based, case-control study of 12 European registries, SSRI exposure in the first trimester of pregnancy was associated with ano-rectal atresia or stenosis, gastroschisis, renal dysplasia, and clubfoot [21]. SSRI exposure was also associated with congenital heart defect (CHD), particularly tetralogy of Fallot and Ebstein’s anomaly [21]. Although these analyses strongly supported the validity of such associations, the increase in absolute risk was small. On the other hand, a multinational population-based cohort study using sibling-controlled analysis within five Nordic countries found no substantial increase in prevalence of overall congenital malformation or any congenital cardiac malformation among infants exposed to SSRIs or to venlafaxine, an SNRI, in utero [22]. Study authors concluded that results from both the adjusted and sibling-controlled analyses indicate against a teratogenic effect for SSRIs and venlafaxine [22].

Several meta-analyses have associated SSRIs with teratogenic risk. One recent study found that pregnant women who were exposed to SSRIs during the first trimester were at increased risk for having an infant with CHD [23]. Another, older study found an increased risk for major malformations but not CHD [24]. Yet another found no association with major malformations but did find an association with CHD and septal defects [25]. One meta-analysis of prospective cohort studies also did not associate first trimester SSRI use with developing CHD [26]. Regarding specific SSRIs, fluoxetine [24][27] and paroxetine [24][25][28] have been associated with higher risk for major malformations and cardiovascular malformations (both septal defects and non-septal defects) in meta-analyses, whereas sertraline and citalopram were not associated with either [24]. In other meta-analyses, fluoxetine was not shown to be associated with either major malformations [25] or cardiac malformations [25][29]. All the studies referenced here were limited by inability to fully control for confounding or ascertainment or detection bias (or both).

To summarize, it remains difficult to determine whether SSRIs or SNRIs are associated with increased risk for teratogenic effects, because while some studies appear to demonstrate an association, others clearly do not. Importantly, however, when an association has been found, the absolute risk was low and the number needed to treat to harm (NNTH) was high. 

Table 1. Epidemiological studies and systematic reviews or meta-analyses of maternal serotonin reuptake inhibitor use in early pregnancy and risk for congenital malformations in infants

Study (year)

Design

(population number)

Cases or exposure numbers

Comparison group (number)

Major malformations

Congenital heart malformations

Comments

Reefhuis (2015) [20]

 

 

 

 

 

Population-based, case-control study (NBDPS, U.S.) (n=38,009)

SSRI use 1 month pre-conception through month 3 of pregnancy (n=1285)

No antidepressants from 3 months before to the end of pregnancy (n=34,843)

Paroxetine:

Anencephaly (OR 3.2, 95% CI 1.6 to 6.2), Gastroschisis (OR 2.5, 95% CI 1.2 to 4.8), Omphalocele (OR 3.5, 95% CI 1.3 to 8.0)

Fluoxetine:

Craniosynostosis (OR 1.9, 95% CI 1.1 to 3.0)

Paroxetine:

ASD (OR 1.8, 95% CI 1.2 to 3.0), RVOTO defects (OR 2.4, 95% CI 1.4 to 3.9)

 

Fluoxetine:

RVOTO defects (OR 2.0, 95% CI 1.4 to 3.1)

For the two strongest associations, paroxetine use increased the rate of anencephaly from 2/10,000 to 7/10,000), and for RVOTO defects from 10/10,000 to 24/10,000

Wemakor (2015) [21]

Population-based, case- control study of 12 EUROCAT registries (n=2.1 million births)

SSRI first trimester of pregnancy (n=13,024 for non-CHD; n=12,876 for CHD)

No antidepressant in first trimester of pregnancy (n=17,083)

Ano-rectal atresia or stenosis (OR 2.46, 95% CI 1.06 to 5.68), Gastroschisis (OR 2.42, 95% CI 1.10 to 5.29)

Renal dysplasia (OR 3.01, 95% CI 1.61 to 5.61)

Clubfoot (OR 2.41, 95% CI 1.59 to 3.65)

CHD (OR 1.41, 95% CI 1.07 to 1.86), severe CHD (OR 1.56, 95% CI 1.02 to 2.39), Tetralogy of Fallot (OR 3.16, 95% CI 1.52 to 6.58), Ebstein’s anomaly (OR 8.23, 95% CI 2.92 to 23.16)

 

Association with septal defects of borderline significance (OR 1.36, 95% CI 0.99 to 1.87)

No association with any specific SSRI

 

NNTH for any major malformation 192 (95% CI 118 to 152), severe CHD 1094 (95% CI 555 to 38,141), abdominal wall defects 1629 (95% CI 832 to 39,830)

Furu et al (2015) [22]

Multinational population- based cohort study, including sibling controlled analysis (5 Nordic countries) (n=2.3 million births)

Women who filled a prescription for an SSRI or SNRI (venlafaxine) during the first trimester (n=36,772)

No antidepressant use in first trimester of pregnancy (n=2,266,875)

Any birth defect (OR, 1.13, 95% CI 1.06 to 1.20); sibling controlled (OR 1.06, 0.91 to 1.24)

CHD (OR, 1.15, 95% CI 1.05 to 1.26), sibling controlled (OR 0.92, 95% CI 0.72 to 1.17)

RVOTO defects (OR 1.48, 95% CI 1.15 to 1.89) and sibling controlled (OR 0.56, 95% CI 0.21 to 1.49)

  

Zhang et al (2017) including Furu et al (2015) [22][23]

Meta-analysis: 18 cohort studies, (sample sizes of individual studies 534 to 2,303,647; number of CHD malformations 6 to 27,309)

SSRI use in the first trimester

No antidepressant use during the first trimester

  

Any CHD (OR 1.26, 95% CI 1.13 to 1.39), ASD (OR 2.06, 95% CI 1.40 to 3.03), VSD (OR 1.15, 95% CI 0.97 to1.36) and ASD and/or VSD (OR 1.27, 95% CI 1.14 to1.42)

  

Wang (2015) [26]

Meta-analysis: 4 cohort studies (n=1,996,519, range 63,395 to 949,504 in individual studies)

SSRI use in the first trimester

No antidepressant use during the first trimester

  

CHD (OR 1.06, 95% CI 0.94 to 1.18)

  

Myles (2013) [24]

Systematic review and meta-analysis: 29 cohort studies and case-control studies, (sample size major malformations, exposed 23,919 and control 2,585,550; CHD malformation, exposed 22,412 and control 2,404,278)

SSRI use in the first trimester

No antidepressant use during the first trimester

Any major malformations (OR 1.10, 95% CI 1.03 to 1.16)

Any CHD (OR 1.15, 95% CI 0.99 to 1.32)

  

Grigoriadis et al (2013a) Grigoriadis et al (2013b)

[6][25]

Systematic review and meta-analysis: 19 cohort studies and case control studies (all studies, cases 56,443 and controls 1,943,538)

Antidepressant use in the first trimester

No exposure to antidepressants

Any major malformations (OR 1.07, 95% CI 0.99 to 1.17)

Any CHD (OR 1.36, 95% CI 1.08 to 1.71), any septal defects (OR 1.40, 95% CI 1.10 to 1.77)

  

ASD Atrial septal defect; CHD Congenital heart defect; CI Confidence interval; EUROCAT European Concerted Action on Congenital Anomalies and Twins; NBDPS National Birth Defects Prevention Study; NNTH Number needed to treat to harm; OR Odds ratio; RVOTO Right ventricular outflow tract obstruction; SSRI Selective serotonin reuptake inhibitor; VSD Ventricular septal defect

Pregnancy outcomes

In two large population studies from Nordic countries, there was no association with antenatal SSRIs and stillbirths or neonatal deaths after adjusting for confounders [30][31]. In several systematic reviews and meta-analyses, antidepressant and SSRI or SNRI use during pregnancy were associated with preterm birth (<37 weeks) (19,32-35) and LBW (<2500 g) [33]. Second and third trimester exposure increased the risk for preterm birth [19]. The pooled mean difference in weeks was -0.45 (95% CI -0.64 to -0.25) and the mean difference for birth weight was -74g (95% CI -117 to -31) [34]. The authors of these meta-analyses cautioned against over-interpreting the clinical significance of such associations [34], due to heterogeneity of samples [33] and residual confounding [19]. By contrast, using a population-based national birth cohort, treatment with SSRIs during pregnancy was related to a lower risk for late preterm birth (OR 0.84, 95% CI 0.74 to 0.96), very preterm birth (OR 0.52, 95% CI 0.37 to 0.74), and caesarean section (OR 0.70, 95% CI 0.66 to 0.75) [36].

Poor neonatal adaptation syndrome (PNAS)

PNAS, also referred to as neonatal withdrawal syndrome and serotonin discontinuation syndrome, has been described in up to 30% of newborns exposed to maternal SSRI or SNRI use in utero, particularly during the third trimester [37]. Symptoms include poor muscle tone, tremors, jitteriness, irritability, seizures, feeding difficulties, sleep disturbances, hypoglycemia, and respiratory distress [37][38]. Although the mechanism of PNAS is not completely understood, symptoms may relate to either a withdrawal from maternal SSRI or SNRI exposure, or overstimulation from serotonin toxicity [37][38]. One systematic review and meta-analysis described an association between exposure to antidepressants and PNAS (OR 5.07, 95% CI 3.25 to 7.90; p<0.001), respiratory distress (OR 2.20, 95% CI 1.81 to 2.66; p<0.001), and tremors (OR 7.89, 95% CI 3.33 to 18.73; p<0.001) [37]. Similarly, a second comparable study reported a risk ratio (RR) of 3.0 (95% CI, 2.0 to 4.4) of late gestational SSRI exposure for PNAS [38].

Persistent pulmonary hypertension of the newborn (PPHN)

PPHN is the final common pathway for a variety of risk factors and insults (e.g., congenital malformations, premature birth, meconium aspiration syndrome, caesarean section) that can cause pulmonary underdevelopment, maldevelopment, or poor postnatal adaptation. In PPHN, vascular resistance in the newborn lung fails to decrease after birth, resulting in right-to-left shunting of blood though fetal channels, decreased pulmonary blood flow, and hypoxia. Infants can present with a wide range of breathing difficulties, from mild respiratory distress to severe respiratory failure requiring intubation and ventilation. In both large cohort studies [39][40] and one systematic review and meta-analysis [41], SSRIs taken late in pregnancy have been associated with increased risk for PPHN, although the absolute risk is low (Table 2). Studies differ by diagnostic criteria, definition, severity of PPHN, and controls for confounders. The biological mechanism for association with PPHN is believed to relate to higher circulating levels of serotonin in the fetus, causing vasoconstriction and smooth muscle proliferation in pulmonary vasculature [41].

Table 2. Cohort studies and meta-analysis of maternal serotonin reuptake inhibitor use in late pregnancy and risk for pulmonary hypertension in the newborn (PPHN)

Study (year)

Design

Case or exposure numbers

Comparison group (number)

Findings

Comments

Huybrechts et al (2015) [39]

Record-linkage cohort (USA)

SSRIs 90 days before delivery (n=102,179)

No antidepressant use throughout pregnancy (n=3,660,380)

Primary PPHN OR 1.58 (95% CI 1.34 to 1-87); AOR 1.28 (95% CI 1.01 to 1.64) for depressed mothers

Not exposed 20.8 (95% CI 20.4 to 21.2/10,000 births) compared with exposed 31.5 (95% CI 28.3 to 35.2/10,000 births)

Kieler et al (2011) [40]

Population based record-linkage cohort (5 Nordic countries)

SSRIs after 20 weeks gestational age

Unexposed to SSRIs throughout pregnancy (n=1,588,140)

AOR 2.1 (95% CI 1.5 to 3.0)

Risk estimates positive for specific SSRIs with similar magnitude (fluoxetine, citalopram, paroxetine, sertraline)

Absolute risk of PPHN after exposure to SSRIs in late pregnancy was 3/1000 live births

Grigoriadis et al (2014) (including Kieler et al (2011)[40][41]

Systematic review and meta-analysis: 3 cohort and 2 case-control studies (sample sizes not provided)

SSRI exposure in late pregnancy

No exposure to antidepressants

OR 2.50, 95% CI 1.32 to 4.73)

Absolute risk difference was 2.9 to 3.5/1000 infants (NNTH 286 to 351)

AOR Adjusted odds ratio; CI Confidence interval; NNTH Number needed to treat to harm; OR Odds ratio; PPHN Persistent pulmonary hypertension of the newborn; SSRI Selective serotonin reuptake inhibitors

Neurodevelopmental outcomes

Several studies have examined the association between prenatal exposure to SSRIs or SNRIs and autism spectrum disorders (ASD) in children [35][42]-[44]. Although there may be an association of increased risk [44], this relationship has not been found consistently [35][42][43] (Table 3). Weakness of association may be explained by confounding by indication for medication use. More recent studies have adjusted for confounding and used sibling and exposure-before-pregnancy comparisons. Genetic factors, familial environment, and maternal mental illness history could each contribute to ASD risk [35][42]-[44]. Similarly, in a population-based cohort study of first trimester antidepressant use, ADHD was diagnosed in 12.63% exposed versus 5.46% unexposed children by 15 years of age (International Classification of Diseases [ICD]-9 and ICD-10 coding), hazard ratio (HR) 2.21 (95% CI 2.01 to 2.39). This finding was more attenuated in the sibling-comparison analysis: HR 0.99 (95% CI 0.79 to 1.25) [35].

Table 3. Cohort studies and systematic review or meta-analysis of maternal serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) use in pregnancy and risk for autism spectrum disorder (ASD)

Study (year)

Design

Case or exposure number

Comparison group (number)

Findings

Comments

Brown  (2017) [42]

Retrospective cohort; diagnosis of ASD by a paediatrician or psychiatrist (Canada)

SSRI or SNRI ≥2 prescriptions filled between conception and delivery (n=2,837)

No antidepressant use before and throughout pregnancy (n=33,069)

HR 1.61 (95% CI 0.997 to 2.59) based on high-dimensional propensity score; HR 1.60 (95% CI 0.69 to 3.74) when compared with unexposed siblings

Incidence of ASD 4.51/1000 person-years exposed versus 2.03 per/1000 person-years unexposed

Sujan et al (2017) [35]

Population-based record-linkage cohort; diagnosis of ASD by ICD-9 or ICD-10 codes (Sweden)

First trimester antidepressant use, including SSRI 90 days before conception, and 90 days after conception (n=22,544, of which 82% or 18,470 exposed to SSRIs)

Unexposed to SSRIs throughout pregnancy (n=1,588,085)

Adjusted HR for SSRIs 1.66 (95% CI 1.46 to 1.89); sibling comparison 0.81 (95% CI 0.58 to 1.14)

5.28% of exposed versus 2.14% of unexposed diagnosed with ASD

Brown (2017) [43]

Systematic review and meta-analysis: 2 cohort and 4 case-control studies, diagnosis of ASD by ICD-9 and ICD-10 coding (sample sizes range from 812 to 57,362 in individual studies)

SSRI exposure late in pregnancy

Unexposed to SSRIs throughout pregnancy

Case-control studies: Any exposure AOR 1.4 (95% CI 1.0 to 2.0) and first trimester AOR 1.7 (95% CI 1.1 to 2.6)

Cohort studies OR 1.5 (95% CI 0.9 to 2.7) and first trimester 1.4 (95% CI 1.0 to 1.9)

  

Mezzacappa et al (2017) [44]

Systematic review and meta-analysis: 3 cohort (n=772,331) and 7 case-control studies (n=117,737): SSRI exposure by first/second/third trimester, diagnosis of ASD by regional disease registry

Exposure to antidepressants during pregnancy

Unexposed to antidepressants during pregnancy

Case-control studies: Any exposure AOR 1.81 (95% CI 1.49 to 2.20) and controlled for past maternal mental illness 1.52 (95% CI 1.09 to 2.12)

Cohort studies HR 1.26 (95% CI 0.91 to 1.74)

Preconception exposure OR 1.77 (95% CI 1.49 to 2.09)

  

AOR Adjusted odds ratio; CI Confidence interval; HR Hazard ratio; ICD-9 International Classification of Disease, Ninth revision; ICD-10 International Classification of Disease, Tenth revision; OR Odds ratio

What monitoring is required in the neonatal period for infants exposed to an SSRI or SNRI in utero?

Review of the literature’s conflicting results for congenital malformation risk (and for cardiac malformation risk in particular) does not support recommending either routine fetal echocardiogram during pregnancy or routine echocardiogram of newborns exposed to SSRIs during the first trimester of pregnancy. Rather, all newborns being assessed for safe discharge [45][46], should have received routine pulse oximetry testing to detect critical congenital heart disease (CCHD) [47]. Focused and possibly repeated assessment is especially important for infants presenting with PPHN, where clinical examination remains the mainstay of detection.

For PNAS, symptoms usually begin within hours of delivery, resolve within days to 2 weeks post-birth, and are generally mild and self-limiting [37][38][48]. Some clinicians use a modified Finnegan score to assess severity of symptoms [37][48][49], although this tool has not been validated for this purpose, and no other standardized tool is available. Based on cohort studies and expert opinion, some study authors have recommended observing infants for 24 h to 48 h post-birth, preferably with their mothers [50][51]. Managing neonates with PNAS includes providing a quiet environment, swaddling, skin-to-skin care, and frequent small feeds [38]. Breastfeeding should be encouraged and supported [37][49]. Discontinuation or tapering of antidepressants near term is unwarranted [16][37]. In some rare cases (<1%), anticonvulsant treatment, fluid management, and respiratory support may be required [13][38]. Hypoglycemia (blood glucose <2.6 mmol/L) has been reported to be more common in infants with PNAS [48][52]. Infants of SSRI-treated mothers were more likely to require admission to a NICU [36][52]: 13.7% for exposed newborns versus 8.2% non-exposed newborns [52]. Long-term sequelae after PNAS have not been well studied [37].

Should mothers using an SSRI or SNRI breastfeed?

There is abundant evidence to support treating maternal depression during the postpartum period with SSRIs [2][53][54]. Women with perinatal depression [9] and exposure to SSRIs during pregnancy [55] are less likely to initiate and sustain breastfeeding. Most evidence regarding the safety of SSRI or SNRI use during breastfeeding has been drawn from case reports or case series, without a comparison population or controlling for confounders [2][12][56][57]. Data on possible effects of SSRI or SNRI exposures in breast milk on infant outcomes and development are also lacking [2][12][56][57]. Breastfeeding is not contraindicated during treatment with SSRI or SNRIs, however. The transfer of both medications into breast milk is known to be low, and uptake by the infant even lower [54][56][57]. Sertraline is favoured over other medications for nursing mothers, with fluoxetine being less preferred [54][56][57].

The many benefits of breastfeeding must be considered when decision-making around SSRI or SNRI use during pregnancy or postpartum. Most study authors recommend that when mothers have been treated for depression successfully during pregnancy, the same drug should be used in the postpartum period, because discontinuation or switching treatments at this vulnerable time could lead to relapse [54][56]. Monitoring infant feeding and growth, and watching for symptoms of possible toxicity (e.g., poor feeding and low weight gain), is also recommended [12][54].

Conclusions

Overall, maternal use of an SSRI or SNRI to treat depression during pregnancy is safe for, and well tolerated by the fetus, whereas untreated maternal depression or anxiety is associated with adverse outcomes for both mother and newborn. Most women who continue SSRI or SNRI treatment during pregnancy have healthy babies. There may be increased risk for PNAS, which is typically self-limiting and treatable by non-pharmacological means. Mothers should be encouraged and supported to breastfeed their infants during treatment with an SSRI or SNRI. The literature is inconsistent regarding the safety of in-utero exposure to SSRIs or SNRIs, including neonatal and neurodevelopmental risks. The interplay among medication-related factors, maternal depression, and genetic and social factors is confounding, while methodological constraints may further limit study results. Data from large prospective studies using adequate sample sizes and appropriate comparisons and adjustments for confounding are still required to establish the iatrogenic effects of SSRI or SNRI type, dosing, timing, and duration during pregnancy and beyond.

Recommendations for clinicians

  • Although non-pharmacological treatments are considered first line, mothers and families must be supported when deciding to use an antidepressant medication during pregnancy or in the postpartum period. Untreated maternal depression or anxiety can adversely affect pregnancy, the newborn, child development, and family functioning.
  • Women who use an SSRI or SNRI during pregnancy should be counselled that the overall risk for congenital malformations or persistent pulmonary hypertension is low.
  • Women who use an SSRI or SNRI during pregnancy should be counselled that the infant may develop poor neonatal adaptation syndrome, though symptoms are usually mild and transient, and respond to a quiet environment, swaddling, skin-to-skin care, and frequent feeding, and typically resolve within days to 2 weeks post-birth.
  • Women who use an SSRI or SNRI during pregnancy should be reassured that behavioural concerns such as autism spectrum disorder and attention-deficit hyperactivity disorder have not been convincingly associated with exposure to these medications in utero.
  • No specific monitoring is recommended for newborns or children who were exposed to an SSRI or SNRI in utero or while breastfeeding. Routine discharge planning and later well child visits should be the same as for non-exposed healthy term and late preterm infants.
  • The benefits of breastfeeding are well established and should be encouraged and supported for mothers using an SSRI or SNRI during pregnancy and in the postpartum period.

Acknowledgements

This position statement has been reviewed by the Community Paediatrics, Drug Therapy and Hazardous Substances, and Mental Health and Developmental Disabilities Committees of the Canadian Paediatric Society. It was also reviewed by members of the Society of Obstetricians and Gynaecologists of Canada (SOGC), Family Physician Advisory (FPA), Clinical Practice Obstetrics (CPO), and Maternal Fetal Medicine (MFM) committees.

CANADIAN PAEDIATRIC SOCIETY FETUS AND NEWBORN COMMITTEE

Members: Nicole Anderson MD (Resident Member), Heidi Budden MD (Board Representative), Mireille Guillot MD (Resident member), Leonora Hendson MD, Thierry Lacaze-Masmonteil MD, PhD (past Chair), Brigitte Lemyre MD, Souvik Mitra MD, Michael R. Narvey MD (Chair), Vibhuti Shah MD
Liaisons: Radha Chari MD, The Society of Obstetricians and Gynaecologists of Canada; James Cummings MD, Committee on Fetus and Newborn, American Academy of Pediatrics; William Ehman MD, College of Family Physicians of Canada; Danica Hamilton RN, Canadian Association of Neonatal Nurses; Roxanne Laforge RN, Canadian Perinatal Programs Coalition; Chantal Nelson PhD, Public Health Agency of Canada; Eugene H. Ng MD, CPS Neonatal-Perinatal Medicine Section
Principal authors: Leonora Hendson MD, Vibhuti Shah MD, Sandra Trkulja

References

  1. Lam RW, Mcintosh D, Wang JL, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry 2016;61(9):510–23.
  2. MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Special populations: Youth, women, and the elderly. Can J Psychiatry 2016;61(9):588–603.
  3. Gavin NI, Gaynes BN, Lohr KN, Metlzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: A systematic review of prevalence and incidence. Obstet Gynecol 2005;106(5 Pt 1):1071–83.
  4. Dennis CE, Falah-Hassani K, Shiri R. Prevalence of antenatal and postnatal anxiety: Systematic review and meta-analysis. Br J Psychiatry 2017;210(5):315–23.
  5. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63(8):898–906.
  6. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: A systematic review and meta-analysis. J Clin Psychiatry 2013;74(4):e321–41.
  7. Jarde A, Morais M, Kingston D, et al. Neonatal outcomes in women with untreated antenatal depression compared with women without depression: A systematic review and meta-analysis. JAMA Psychiatry 2016;73(8):826–37.
  8. Grigoriadis S, Graves L, Peer M, et al. Maternal anxiety during pregnancy and the association with adverse perinatal outcomes. J Clin Psychiatry 2018;79(5):17r12011.
  9. Earls MF, Yogman MW, Mattson G, Rafferty J; AAP Committee on Psychosocial Aspects of Child and Family Health. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics 2019;143(1):e20183259.
  10. Bernard-Bonnin AC, Canadian Paediatric Society, Mental Health and Developmental Disabilities Committee. Maternal depression and child development. Paediatr Child Health 2004;9(8):575–83.
  11. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295(5):499–507.
  12. McAllister-Williams RH, Baldwin DS, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol 2017;31(5):519–52.
  13. Hayes RM, Wu P, Shelton RC, et al. Maternal antidepressant use and adverse outcomes: A cohort study of 228,876 pregnancies. Am J Obstet Gynecol 2012;207(1):49.e1–9.
  14. Andrade SE, Reichman ME, Mott K, et al. Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration’s Mini-Sentinel program. Arch Womens Ment Health 2016;19(6):969–77.
  15. Zoega H, Kieler H, Nørgaard M, et al. Use of SSRI and SNRI antidepressants during pregnancy: A population-based study from Denmark, Iceland, Norway and Sweden. PLoS One 2015;10(12):e0144474.
  16. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114(3):703–13.
  17. Howard LM, Molyneaux E, Dennis CE, Rochat T, Stein A, Milgrom J. Non-psychotic mental disorders in the perinatal period. Lancet 2014;384(9956):1775–88.
  18. Jefferies AL, Canadian Paediatric Society, Fetus and Newborn Committee. Selective serotonin reuptake inhibitors in pregnancy and infant outcomes. Paediatr Child Health 2011;16(9):562–3.
  19. Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: A systematic review and meta-analysis. PLoS One 2014;9(3):e92778.
  20. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; National Birth Defects Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 2015;351:h3190.
  21. Wemakor A, Casson K, Garne E, et al. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: A European register-based study. Eur J Epidemiol 2015;30(11):1187–98.
  22. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: Population based cohort study and sibling design. BMJ 2015;350:h1798.
  23. Zhang TN, Gao SY, Shen ZQ, et al. Use of selective serotonin-reuptake inhibitors in the first trimester and risk of cardiovascular-related malformations: A meta-analysis of cohort studies. Sci Rep 2017;7:43085.
  24. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry 2013;47(11):1002–12.
  25. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74(4);e293-308.
  26. Wang S, Yang L, Wang L, Gao L, Xu B, Xiong Y. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: A meta-analysis of prospective cohort studies. J Am Heart Assoc2015;4(5):1–8.
  27. Gao SY, Wu QJ, Zhang TN, et al. Fluoxetine and congenital malformations: A systematic review and meta-analysis of cohort studies. Br J Clin Pharmacol 2017;83(10):2134–47.
  28. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88(3):159–70.
  29. Riggin L, Frankel Z, Moretti M, Pupco A, Koren G. The fetal safety of fluoxetine: A systematic review and meta-analysis. J Obstet Gynaecol Canada 2013;35(4):362–9.
  30. Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA. 2013;309(1):48–54.
  31. Jimenez-Solem E, Andersen JT, Petersen M, et al. SSRI use during pregnancy and risk of stillbirth and neonatal mortality. Am J Psychiatry 2013;170(3):299–304.
  32. Eke AC, Saccone G, Berghella V. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: A systematic review and meta-analysis. BJOG 2016;123(12):1900–7.
  33. Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014;36(1):13–8.
  34. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-analysis. JAMA Psychiatry 2013;70(4):436–43.
  35. Sujan AC, Rickert ME, Öberg AS, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA 2017;317(15):1553-62.
  36. Malm H, Sourander A, Gissler M, et al. Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: Results from population-based national register data. Am J Psychiatry 2015;172(12):1224–32.
  37. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis. J Clin Psychiatry 2013;74(4);e309–20.
  38. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA 2005;293(19):2372–83.
  39. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA - J Am Med Assoc. 2015;313(21):2142–51.
  40. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: Population based cohort study from the five Nordic countries. BMJ 2011;344:d8012.
  41. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: Systematic review and meta-analysis. BMJ 2014;348:f6932.
  42. Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children. JAMA 2017;317(15):1544-52.
  43. Brown HK, Hussain-Shamsy N, Lunsky Y, Dennis CE, Vigod SN. The association between antenatal exposure to selective serotonin reuptake inhibitors and autism: A systematic review and meta-analysis. J Clin Psychiatry 2017;78(1):e48–58.
  44. Mezzacappa A, Lasica PA, Gianfagna F, et al. Risk for autism spectrum disorders according to period of prenatal antidepressant exposure: A systematic review and meta-analysis. JAMA Pediatr 2017;171(6):555–63.
  45. Lemyre B, Jefferies AL, O’Flaherty P, Canadian Pediatrics Society, Fetus and Newborn Committee. Facilitating discharge from hospital of the healthy term infant. Paediatr Child Health2018;23(8):515–31: https://cps.ca/en/documents/position/facilitating-discharge-from-hospital-of-the-healthy-term-infant
  46. Jefferies AL, Canadian Paediatric Society, Fetus and Newborn Committee. Going home: Facilitating discharge of the preterm infant. Paediatr Child Health 2014;19(1):31–42: https://cps.ca/en/documents/position/facilitating-discharge-of-the-preterm-infant
  47. Narvey M, Wong KK, Fournier A; Canadian Pediatric Society, Fetus and Newborn Committee. Pulse oximetry screening in newborns to enhance detection of critical congenital heart disease. Paediatr Child Health 2017;22(8):494–503: https://cps.ca/en/documents/position/pulse-oximetry-screening
  48. Forsberg L, Navér L, Gustafsson LL, Wide K. Neonatal adaptation in infants prenatally exposed to antidepressants— Clinical monitoring using neonatal abstinence score. PLoS One 2014;9(11):e111327.
  49. Kieviet N, Hoppenbrouwers C, Dolman KM, Berkhof J, Wennink H, Honig A. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. Acta Paediatr 2015;104(4):384–91.
  50. Leibovitch L, Rymer-Haskel N, Schushan-Eisen I, Kuint J, Strauss T, Maayan-Metzger A. Short-term neonatal outcome among term infants after in utero exposure to serotonin reuptake inhibitors. Neonatology 2013;104(1):65–70.
  51. Perinatal Services BC. Perinatal services BC antidepressant use during pregnancy: Considerations for the newborn exposed to SSRIs/SNRIs, May 2013: www.perinatalservicesbc.ca/Documents/Guidelines-Standards/Newborn/AntidepressantUseExposedNewbornGuideline.pdf (Accessed July 8, 2020)
  52. Nörby U, Forsberg L, Wide K, Sjörs G, Winbladh B, Källen K. Neonatal morbidity after maternal use of antidepressant drugs during pregnancy. Pediatrics 2016;138(5):e20160181.
  53. Molyneaux E, Howard LM, McGeown HR, Karia AM, Trevillion K. Antidepressant treatment for post-natal depression. Cochrane Database Syst Rev 2014;(9):CD002018.
  54. Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: Use of antidepressants in breastfeeding mothers. Breastfeed Med 2015;10(6):290–9.
  55. Gorman JR, Kao K, Chambers CD. Breastfeeding among women exposed to antidepressants during pregnancy. J Hum Lact 2012;28(2):181–8.
  56. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev 2011;7(1):28–34.
  57. Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: A systematic review. Hum Psychopharmacol 2015;30(1):4–20.

Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.

Last updated: Feb 8, 2024

In this section

Related information

statements and practice points

Paediatrics & Child Health